| Literature DB >> 35744949 |
Dandan Xin1,2, Huhu Li3, Shiyue Zhou1,2, Hao Zhong1,2, Weiling Pu1,2.
Abstract
The anthraquinones (AQs) and derivatives are widely distributed in nature, including plants, fungi, and insects, with effects of anti-inflammation and anti-oxidation, antibacterial and antiviral, anti-osteoporosis, anti-tumor, etc. Inflammation, including acute and chronic, is a comprehensive response to foreign pathogens under a variety of physiological and pathological processes. AQs could attenuate symptoms and tissue damages through anti-inflammatory or immuno-modulatory effects. The review aims to provide a scientific summary of AQs on immune responses under different pathological conditions, such as digestive diseases, respiratory diseases, central nervous system diseases, etc. It is hoped that the present paper will provide ideas for future studies of the immuno-regulatory effect of AQs and the therapeutic potential for drug development and clinical use of AQs and derivatives.Entities:
Keywords: anthraquinones; immune system; inflammation; inflammatory diseases
Mesh:
Substances:
Year: 2022 PMID: 35744949 PMCID: PMC9230691 DOI: 10.3390/molecules27123831
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Chemical structure of AQs mentioned in this paper.
Effects and mechanism of AQs on immune system.
| Compound | Disease/Injury | Stimuli | Cell/Animal | Doses | Effects | Mechanism | Ref |
|---|---|---|---|---|---|---|---|
| Aloe-emodin | In vitro | LPS | RAW264.7 | 10–20 μM | NO, IL-6, and IL-1β↓ | NF-κB↓ | [ |
| Emodin | In vitro | LPS | RAW264.7 | 25 μM | ICAM-1, MCP-1 and TNFα↓ | NF-κB↓; PPARγ↑ | [ |
| Emodin | In vitro | LPS | RAW264.7 | 0–50 μM | TNFα IL-1β and IL-6↓ | NF-κB↓; | [ |
| Emodin | In vitro | LPS/IL-4 | Primary macrophages | 0–50 μM | Phagocytosis↓; | NF-κB/IRF5/STAT1↓(LPS) | [ |
| Emodin | In vitro | ATP | peritoneal macrophages | 0.1–10 μM | cytosolic Ca2+↓; phagocytosis↓ | P2X7↓ | [ |
| Emodin | Autoimmune thyroiditis | NaI | non-obese diabetic mice | ig. 15, 75 or 150 mg/kg | serum TgAb↓ | CD3+CD4+ T cell↓ | [ |
| Emodin | In vitro | _ | Primary human T cells | 1–100 μM | Apoptosis↑; Ca2+ | Endoplasmic reticulum stress↑ | [ |
| Emodin 8-O-glucoside | In vitro | LPS | RAW264.7 | 20 μM | TNFα, IL-6, NO↑ | TLR-2/MAPK/NF-κB ↑ | [ |
| Rhein | In vitro | LPS | RAW264.7 | 60–140 μM | iNOS and TNFα↓ | NF-κB↓; PPARγ↑ | [ |
| Rhein micelles | In vitro | LPS | RAW264.7 | 40 μM | iNOS, TNFα, IL-1β, and IL-6↓ | NF-κB↓ | [ |
| Rhein | In vitro | LPS | RAW264.7 | 0–35 μM | NO, IL-6↓ | NF-κB↓ | [ |
| Rhein | In vitro | LPS + ATP | RAW264.7 | 1–20 μM | TNFα, IL-1β, and IL-6↓ | NF-κB↓ | [ |
| Rhein | In vitro | ATP | peritoneal macrophages | 0–10 μM | cytosolic Ca2+↓; Phagocytosis↓ | P2X7↓ | [ |
| Chrysophanol | In vitro | LPS | RAW264.7 | 15 μM | iNOS, TNFα and IL-1β↓ | NF-κB↓; PPARγ↑ | [ |
| Physcion | In vitro | _ | Primary dendritic cells | 1–100 μM | DCs maturation↑ | CD40, CD80, CD86, and MHC II↑; IL-12p70↑ | [ |
Effects and mechanism of AQs on digestive diseases.
| Compound | Disease/Injury | Stimuli | Cell/Animal | Doses | Effects | Mechanism | Ref |
|---|---|---|---|---|---|---|---|
| Rhein | Intestinal barrier injury | LPS ip. | SD rats | ig. 66.7 mg/kg/day | intestinal damage↓ | MAPK↓ | [ |
| Rhein | In vitro | TNFα | IEC-6 | 0–4 μM | TNFα, IL-1 and IL-6↓; ZO-1↑ | MLCK and NF-κB↓ | [ |
| Rhein | Ulcerative colitis | DSS | C57BL/6J mice | ig. 50, 100 mg/kg/day, ig. | Histological changes↓ | Probiotic | [ |
| Rhein | Acute enteritis | Radiation | SD rats | ig. 90 μg/kg | NO, TNFα IL-1β and IL-6↓ | NF-κB ↓; PPARγ↑ | [ |
| Emodin | Colitis-associated tumorigenesis | AOM + DSS | BALB/c mice | ig. 50 mg/kg/day | Week 3: adenoma↓ | _ | [ |
| Emodin | Sepsis-induced jejunum injury | Cecal ligation and puncture | Wistar rats | ip. 10 mg/kg/day | Intestinal mucosal damage↓ | JAK1/STAT3↑ | [ |
| Emodin | In vitro | Cerulein/LPS | AR42J | 10–40 μM | Mitochondrial damage↓; ROS↓; | ASK1/TRAF2 (JNK)↓ | [ |
| Emodin | SAP | Taurocholate | SD rats | ig. 60 mg/kg | TNFα, IL-6↓ | VDAC1↓ | [ |
| Emodin | SAP | Taurocholate | SD rats | ig. 30, 60 mg/kg | Pathological changes | P2X7↓ | [ |
| Emodin | SAP | Taurocholate | SD rats | ig. 50 mg/kg | Intestine mucosal barrier↑ | Notch1, RhoA/ROCK↓ | [ |
| Rhein | In vitro | Cerulein | AR42J | 1 μM | Mitochondrial swelling and spinal fracture↓ | PI3K/AKT/mTOR↓ | [ |
| Total Rhubarb anthraquinones | SAP | Taurocholate | SD rats | ig. 36, 72 mg/kg | Endotoxin, TNFα, IL-1β↓ | NLRP3 inflammasome↓ | [ |
Effects and mechanism of AQs on respiratory diseases.
| Compound | Disease/Injury | Stimuli | Cell/Animal | Doses | Effects | Mechanism | Ref |
|---|---|---|---|---|---|---|---|
| Emodin | ALI | LPS | Wistar rats | ig. 20, 40 mg/kg | Pathological changes↓; | mTOR/HIF-1α/VEGF↓ | [ |
| Emodin | ARDS | LPS | C57BL/6J mice | ip. 5, 10, 20 mg/kg | Lung injury, inflammatory infiltration↓ | NF-κB↓ | [ |
| Emodin | Lung function decreases | DEP air pollution | BALB/C mice | ip. 4 mg/kg | Lung function↑ | _ | [ |
| Emodin | Asthma | Ovalbumin | BALB/c mice | ip. 15, 30, 60 mg/kg | Airway resistance↓ | Notch1-3↓ | [ |
| Emodin | Asthma | Ovalbumin | C57BL/6J mice | ip. 10, 20 mg/kg | Macrophages and eosinophils↓ | _ | [ |
| Emodin | pulmonary fibrosis | Bleomycin | SD rats | ig. 20 mg/kg | Lung structural damage↓; | NF-κB↓ | [ |
| Emodin | In vitro | TGFβ1 | A549 | 60 μM | EMT↓ | ||
| Emodin | Silicosis | Silica | C57BL/6J mice | ig. 25, 50 mg/kg | alveolitis and fibrosis↓ | NF-κB↓ | [ |
| Chrysophanol | ALI | LPS | BALB/c mice | ip. 7.5, 15, and 30 mg/kg) | Lung injury↓ | HMGB1/NF-κB↓ | [ |
| Chrysophanol | Asthma | Ovalbumin | BALB/c mice | ip. 0.1, 1, 10 mg/kg | TNFα,IL-4, IL-5, IL-13↓ | NF-κB↓ | [ |
| Chrysophanol | In vitro | TNFα | BEAS-2B | 2, 20 μM | Proliferation↓, p-IκB↓ |
Effects and mechanism of AQs on arthritis.
| Compound | Disease/Injury | Stimuli | Cell/Animal | Doses | Effects | Mechanism | Ref |
|---|---|---|---|---|---|---|---|
| Rhein | In vitro | PMA/urate | THP-1 | 1–10 μg/mL | IL-1β, TNFα, Caspase1↓ | NLRP3 inflammasome↓ | [ |
| Rhein | In vitro | ATP | Synoviocytes of CIA rats | 0.1–10 μM | Ca2+↓; ROS↓ | P2 × 4R | [ |
| Emodin | RA | Collagen | DBA/1 mice | ip. 10 mg/kg | Synovial inflammation↓ | NF-κB↓ | [ |
| Emodin | In vitro | LPS | Synoviocytes of RA patients | 0.1–10 μM | TNFα, IL-6 and IL-8↓ | HDAC1↓ | [ |
| Emodin | In vitro | _ | Fibroblasts of AS patients | 10 µM | Caspase-3, -9↑ | autophagy↑ | [ |
| Aloe-emodin | RA | Complete Freund’s Adjuvant | Wistar rats | 50 and 75 mg/kg | paw edema volume↓ | — | [ |
Effects and mechanism of AQs on metabolic disorder.
| Compound | Disease/Injury | Stimuli | Cell/Animal | Doses | Effects | Mechanism | Ref |
|---|---|---|---|---|---|---|---|
| Emodin | NAFLD | HFD + LPS | LDLR−/− mice | ip. 40 mg/kg | TNFα, IL-1β, IL-6, IFNγ, G-CSF, GM-CSF, MCP-1, RANTES↓; | Erk1/2 and p38↓ | [ |
| Emodin | Obesity | HFD | C57BL/6 mice | ig. 80 mg/kg | glucose and insulin↓ | M2 macrophage↑ | [ |
| Emodin | T2D | HFD + streptozotocin | T2D | Hyperglycemia, dyslipidemia↓ | miR-20b/SMAD 7 | [ | |
| Emodin | In vitro | Palmitic acid | L6 myoblasts | 5–20 μM | Glucose consumption↑ | ||
| Emodin | In vitro | _ | C2C12/3T3-L1 | 6.25–50 μM | Glucose uptake, consumption↑ | NF-κB↓ | [ |
| Chrysophanol | Obesity | HFD | SD rats | ip. 10 mg/kg | Body weight, blood glucose↓ | AMPK/Sirt1↑ | [ |
| Aloe-emodin | Obesity | HFD | Wistar rats | ig. 100 mg/kg | TNFα, IL-1β, IL-6↓ | TLR4/NF-κB↓ | [ |
Effects and mechanism of AQs on cerebral vascular diseases and central nervous system.
| Compound | Disease/Injury | Stimuli | Cell/Animal | Doses | Effects | Mechanism | Ref |
|---|---|---|---|---|---|---|---|
| Chrysophanol | Stroke | MCAO | CD1 mice | ip. 0.1,1, 10 mg/kg | Neurons Caspase-1, IL-1β↓ | NALP3↓ | [ |
| Chrysophanol | Stroke | MCAO | C57BL mice | ip. 0.1,1, 10 mg/kg | Survival rates↑, apoptosis↓ | NF-κB↓ | [ |
| Aloe-emodin | Stroke | MCAO | SD rats | ig. 25, 50, 100 mg/kg | Neurological disorder↓ | PI3K/AKT/mTOR↓ | [ |
| Aloe-emodin | in vitro | OGD/R | SH-SY5Y | 0–10 µM | |||
| Emodin | in vitro | H2O2 | SH-SY5Y | 10–100 µM | Viability↑, Apoptosis, LDH↑ | PI3K/mTOR/GSK3β | [ |
| Emodin | SAE | Cecal ligation and puncture (CLP) | BALB/C mice | i.p. 20 mg/kg | Neurons apoptosis↓ | BDNF/TrkB↑ | [ |
| Emodin | sepsis-realted brain injury | LPS | BALB/c mice | ip. 20 mg/kg | Serum S100β, IL-6, TNFα, NSE↓ | _ | [ |
| Rhein | Multiple sclerosis | EAE | Mice | ip. 5, 10, 20 mg/kg | Brain IL-2↓, Foxp3↑ | Treg differentiation | [ |
Effects and mechanism of AQs on liver and kidney injury.
| Compound | Disease/Injury | Stimuli | Cell/Animal | Doses | Effects | Mechanism | Ref |
|---|---|---|---|---|---|---|---|
| Rhein | DILI | MTX | Wistar rats | ig. 20, 50 and 100 mg/kg | ALT, AST, morphological damage↓ | NF-κB↓ | [ |
| Rhein | In vitro | MTX | L02 | 5, 10, 20 μM | TNFα, caspase-3↓ | ||
| Rhein | In vitro | Uric acid | TCMK-1 | 10, 20 and 40 μg/mL | TNFα, IL-1β, and IL-6↓ | miR-150-5p/STAT1 | [ |
| Emodin | DILI | APAP | C57B/6 mice | ig. 10, 30 mg/kg | ALT, AST↓, tissue damage↓ | AMPK-Hippo/Yap↑ | [ |
| Emodin | In vitro | APAP | HepG2 | 3–30 μM | Cell death↓, ROS↓, | ||
| Emodin | In vitro | Glucose | SV40-MES13 | 20, 40 μm | MDA, ROS↓, SOD↑ | Circ_0000064/miR-30c-5p/Lmp7 | [ |
| Emodin | In vitro | LPS | NRK-52E | 20, 40 μm | TNFα, IL-1β, and IL-6↓ | TLR2-NF-κB | [ |
| Physcion | ALD | Ethanol | C57BL/6 | ig. 250, 500 μg kg | Fat vacuole accumulation | BMAL1 | [ |
| Physcion | In vitro | Ethanol | HepG2 | 0.125, 0.25 μm | IL-1β and Caspase-1↓ |
Figure 2Effects and mechanism of AQs on inflammatory diseases/injury.